| scholarly article | Q13442814 |
| P356 | DOI | 10.1128/IAI.70.8.4329-4335.2002 |
| P8608 | Fatcat ID | release_kh6oru36hbdsxefojy7c4hmedq |
| P932 | PMC publication ID | 128201 |
| P698 | PubMed publication ID | 12117942 |
| P50 | author | Stephen L. Hoffman | Q60231547 |
| P2093 | author name string | William O Rogers | |
| Dharmendar Rathore | |||
| Sanjai Kumar | |||
| Robert Gwadz | |||
| Kalpana Gowda | |||
| Anita Kumar | |||
| John A Tine | |||
| Joseph G Harre | |||
| Walter R Weiss | |||
| João C Aguiar | |||
| P2860 | cites work | Multistage multiantigen heterologous prime boost vaccine for Plasmodium knowlesi malaria provides partial protection in rhesus macaques | Q24548638 |
| Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine | Q24650662 | ||
| Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products | Q24678867 | ||
| Development of a preventive vaccine for Ebola virus infection in primates | Q28140401 | ||
| Protective Immunity produced by the Injection of X-irradiated Sporozoites of Plasmodium berghei | Q28259011 | ||
| Improving protective immunity induced by DNA-based immunization: priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus | Q33902570 | ||
| Pre-erythrocytic-stage immune effector mechanisms in Plasmodium spp. infections | Q35211719 | ||
| Preliminary studies on vaccination of rhesus monkeys with irradiated sporozoites of Plasmodium knowlesi and characterization of surface antigens of these parasites | Q36674716 | ||
| Expression in recombinant vaccinia virus of the equine herpesvirus 1 gene encoding glycoprotein gp13 and protection of immunized animals | Q36830970 | ||
| Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. | Q39417737 | ||
| Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria. | Q39824887 | ||
| Cloning and expression of foreign genes in vaccinia virus, using a host range selection system | Q40116789 | ||
| Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC. | Q40554014 | ||
| Origin, maturation and antigen presenting function of dendritic cells. | Q40906220 | ||
| Attempts to Immunize Monkeys Against Plasmodium knowlesi by using Heat-Stable, Serum-Soluble Antigens | Q41267055 | ||
| Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. | Q44022556 | ||
| Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara | Q44138669 | ||
| Immunization of man against sporozite-induced falciparum malaria | Q44157817 | ||
| The complexity of protective immunity against liver-stage malaria | Q44444824 | ||
| A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine. | Q45247428 | ||
| Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine | Q45739411 | ||
| Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations | Q45749670 | ||
| An improved plasmid DNA expression vector for direct injection into skeletal muscle | Q45878158 | ||
| Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine | Q47837811 | ||
| Plasmid vaccine expressing granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles | Q47872885 | ||
| ELISPOT assay for detection of peptide specific interferon-gamma secreting cells in rhesus macaques | Q47876181 | ||
| World malaria situation in 1992. Part I | Q72890955 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | malaria | Q12156 |
| Plasmodium knowlesi | Q241594 | ||
| immunization | Q1415366 | ||
| P304 | page(s) | 4329-4335 | |
| P577 | publication date | 2002-08-01 | |
| P1433 | published in | Infection and Immunity | Q6029193 |
| P1476 | title | Protection of rhesus macaques against lethal Plasmodium knowlesi malaria by a heterologous DNA priming and poxvirus boosting immunization regimen | |
| P478 | volume | 70 |
| Q38528578 | A Review of Plasmodium coatneyi-Macaque Models of Severe Malaria |
| Q40415127 | A heterologous prime/boost immunisation strategy protects against virulent E. ruminantium Welgevonden needle challenge but not against tick challenge. |
| Q28253333 | A large focus of naturally acquired Plasmodium knowlesi infections in human beings |
| Q35689495 | A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites |
| Q28744136 | Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component |
| Q60909088 | Age-Related Differential Stimulation of Immune Response by and During Acute Phase of Infection Affects Disease Severity |
| Q34298647 | Baculovirus-vectored multistage Plasmodium vivax vaccine induces both protective and transmission-blocking immunities against transgenic rodent malaria parasites |
| Q36694820 | Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA |
| Q35771456 | Combining liver- and blood-stage malaria viral-vectored vaccines: investigating mechanisms of CD8+ T cell interference |
| Q26775082 | Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection |
| Q61811321 | Cytomegalovirus vectors expressing Plasmodium knowlesi antigens induce immune responses that delay parasitemia upon sporozoite challenge |
| Q35165007 | DNA immunization with the cysteine-rich interdomain region 1 of the Plasmodium falciparum variant antigen elicits limited cross-reactive antibody responses |
| Q33208276 | DNA vaccines and their application against parasites--promise, limitations and potential solutions. |
| Q35949699 | Enhanced immunity to Plasmodium falciparum circumsporozoite protein (PfCSP) by using Salmonella enterica serovar Typhi expressing PfCSP and a PfCSP-encoding DNA vaccine in a heterologous prime-boost strategy |
| Q47991262 | Enhanced protective immunity against malaria by vaccination with a recombinant adenovirus encoding the circumsporozoite protein of Plasmodium lacking the GPI-anchoring motif |
| Q81583836 | Evaluation of immune response to recombinant potential protective antigens of Mycoplasma hyopneumoniae delivered as cocktail DNA and/or recombinant protein vaccines in mice |
| Q36407775 | GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine |
| Q36726723 | High road, low road? Choices and challenges on the pathway to a malaria vaccine |
| Q34034224 | Identification, cloning, expression, and characterization of the gene for Plasmodium knowlesi surface protein containing an altered thrombospondin repeat domain |
| Q47989426 | Immune responses elicited by co-immunization of Plasmodium vivax and P. falciparum MSP-1 using prime-boost immunization strategies |
| Q48031825 | Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMA1)-based DNA, protein and recombinant modified vaccinia Ankara vaccines |
| Q35824686 | Incorporation of a GPI-anchored engineered cytokine as a molecular adjuvant enhances the immunogenicity of HIV VLPs |
| Q81781516 | Induction of active immune suppression by co-immunization with DNA- and protein-based vaccines |
| Q36285998 | Induction of multi-antigen multi-stage immune responses against Plasmodium falciparum in rhesus monkeys, in the absence of antigen interference, with heterologous DNA prime/poxvirus boost immunization. |
| Q52943376 | Induction of neutralising antibodies restricts the use of human granulocyte/macrophage colony stimulating factor for vaccine studies in rhesus macaques. |
| Q36541222 | Induction of protective immunity against malaria by priming-boosting immunization with recombinant cold-adapted influenza and modified vaccinia Ankara viruses expressing a CD8+-T-cell epitope derived from the circumsporozoite protein of Plasmodium y |
| Q33214292 | Induction of strain-transcending immunity against Plasmodium chabaudi adami malaria with a multiepitope DNA vaccine |
| Q34615872 | Malaria infection by sporozoite challenge induces high functional antibody titres against blood stage antigens after a DNA prime, poxvirus boost vaccination strategy in Rhesus macaques |
| Q35630416 | Malaria vaccine developments |
| Q47933731 | Molecular mechanism of host specificity in Plasmodium falciparum infection: role of circumsporozoite protein |
| Q56769059 | Multi-epitope recombinant vaccine induces immunoprotection against mixed infection of Eimeria spp |
| Q47154921 | Novel Plasmodium antigens identified via genome-based antibody screen induce protection associated with polyfunctional T cell responses. |
| Q38784765 | Plasmodium knowlesi: a relevant, versatile experimental malaria model |
| Q36403400 | Pre-erythrocytic malaria vaccines: towards greater efficacy |
| Q35826388 | Progress in DNA-based heterologous prime-boost immunization strategies for malaria |
| Q33303670 | Protection of rhesus monkeys by a DNA prime/poxvirus boost malaria vaccine depends on optimal DNA priming and inclusion of blood stage antigens |
| Q99635796 | Quantification of Plasmodium knowlesi versus Plasmodium falciparum in the rhesus liver: implications for malaria vaccine studies in rhesus models |
| Q44053738 | Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A. |
| Q33492290 | Sterile protection against Plasmodium knowlesi in rhesus monkeys from a malaria vaccine: comparison of heterologous prime boost strategies |
| Q45416054 | Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine |
| Q26825650 | Successful vaccines for naturally occurring protozoal diseases of animals should guide human vaccine research. A review of protozoal vaccines and their designs |
| Q28084325 | The March Toward Malaria Vaccines |
| Q38577638 | The march toward malaria vaccines |
| Q33805512 | Using infective mosquitoes to challenge monkeys with Plasmodium knowlesi in malaria vaccine studies |
| Q43541858 | Vaxfectin enhances both antibody and in vitro T cell responses to each component of a 5-gene Plasmodium falciparum plasmid DNA vaccine mixture administered at low doses |
Search more.